RAPID: Immunogenicity of SARS-CoV2 to Human T Cells

RAPID:SARS-CoV2 对人类 T 细胞的免疫原性

基本信息

  • 批准号:
    2026995
  • 负责人:
  • 金额:
    $ 12.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
    Standard Grant
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-01 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

Pandemics caused by infectious pathogens have plagued humanity since antiquity. The Coronavirus Disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is currently spreading across the world rapidly, including in the United States, with major adverse impact on health and the economy. The SARSCoV-2 outbreak has led to several urgent efforts to develop vaccines that may offer protection against this virus. It is unknown as to whether the current approaches being pursued will elicit protective immune responses in humans. While vaccines have been very effective against many pathogens, the empirical methods for vaccine development pioneered by Pasteur and Jenner over two centuries ago have failed to produce effective vaccines against Human Immune Deficiency Virus, Malaria, Tuberculosis, and many other pathogens. Therefore, rational design of vaccines based on a mechanistic understanding of the pertinent virology and immunology is being pursued, and these efforts include work that is rooted in statistical physics. SARSCoV-2 is phylogenetically most similar to SARS-CoV. This project will use a machine learning approach to understand how the SARS-CoV-2 virus interacts with the immune T cells. This work will directly impact the design of SARS-CoV-2 vaccines and vaccines against future endemic-causing pathogens.Analyses of patients who have recovered from SARS-CoV shows that antibody responses are not prevalent a few years later, but memory T cell responses are durable and may offer long-term protection. The main questions addressed by this project are 1. Will the SARS-CoV peptides targeted by human T cells that are mutated in SARS-CoV-2 still elicit human T cell responses - i.e. are they immunogenic? 2: Are the 102 peptides identified by host major histocompatibility molecules binding assays alone that are common between SARS-CoV and SARS-CoV-2 immunogenic in humans? If not, they are irrelevant from vaccine design perspective. The goal of the work proposed here is to take a physics-based machine learning approach to determine the immunogenicity of SARS-CoV-2 proteins to human T cell responses.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
自古以来,传染性病原体引起的流行病一直困扰着人类。由 SARS-CoV-2 病毒引起的 2019 年冠状病毒病(COVID-19)目前正在世界范围内迅速传播,其中包括美国,对健康和经济产生了重大不利影响。 SARSCoV-2 的爆发引发了多项紧急努力,以开发可针对该病毒提供保护的疫苗。目前尚不清楚目前正在采用的方法是否会在人类中引发保护性免疫反应。虽然疫苗对许多病原体非常有效,但巴斯德和詹纳在两个多世纪前开创的疫苗开发经验方法未能生产出针对人类免疫缺陷病毒、疟疾、结核病和许多其他病原体的有效疫苗。因此,人们正在追求基于对相关病毒学和免疫学的机械理解的疫苗的合理设计,这些努力包括植根于统计物理学的工作。 SARSCoV-2 在系统发育上与 SARS-CoV 最相似。该项目将使用机器学习方法来了解 SARS-CoV-2 病毒如何与免疫 T 细胞相互作用。这项工作将直接影响 SARS-CoV-2 疫苗和针对未来流行病原体的疫苗的设计。对 SARS-CoV 康复患者的分析表明,几年后抗体反应并不普遍,但记忆 T 细胞反应是持久的,可能提供长期保护。该项目要解决的主要问题是 1. SARS-CoV-2 中突变的人类 T 细胞靶向的 SARS-CoV 肽是否仍会引起人类 T 细胞反应 - 即它们是否具有免疫原性? 2:仅由宿主主要组织相容性分子结合测定鉴定出的 102 种肽是否在人类 SARS-CoV 和 SARS-CoV-2 免疫原性之间常见?如果不是,从疫苗设计的角度来看它们就无关紧要。这里提出的工作目标是采用基于物理的机器学习方法来确定 SARS-CoV-2 蛋白对人类 T 细胞反应的免疫原性。该奖项反映了 NSF 的法定使命,并通过使用基金会的智力价值和更广泛的影响审查标准进行评估,被认为值得支持。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inferring the intrinsic mutational fitness landscape of influenzalike evolving antigens from temporally ordered sequence data
从时间顺序序列数据推断流感样进化抗原的内在突变适应性景观
  • DOI:
    10.1103/physreve.105.024401
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    2.4
  • 作者:
    Doelger, Julia;Kardar, Mehran;Chakraborty, Arup K.
  • 通讯作者:
    Chakraborty, Arup K.
Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2.
  • DOI:
    10.1016/j.isci.2021.102311
  • 发表时间:
    2021-04-23
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Gao A;Chen Z;Amitai A;Doelger J;Mallajosyula V;Sundquist E;Pereyra Segal F;Carrington M;Davis MM;Streeck H;Chakraborty AK;Julg B
  • 通讯作者:
    Julg B
Population extinction on a random fitness seascape
随机适应度海景上的种群灭绝
  • DOI:
    10.1103/physreve.102.052106
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    2.4
  • 作者:
    Ottino-Löffler, Bertrand;Kardar, Mehran
  • 通讯作者:
    Kardar, Mehran
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arup Chakraborty其他文献

Efficacy of formative evaluation using a focus group for a large classroom setting in an accelerated pharmacy program
  • DOI:
    10.1016/j.cptl.2017.03.004
  • 发表时间:
    2017-07-01
  • 期刊:
  • 影响因子:
  • 作者:
    Shaun Nolette;Alyssa Nguyen;David Kogan;Catherine Oswald;Alana Whittaker;Arup Chakraborty
  • 通讯作者:
    Arup Chakraborty
Rectification of high-frequency artifacts in EIS data of three-electrode Li-ion cells
三电极锂离子电池电化学阻抗谱数据中高频伪影的校正
  • DOI:
    10.1016/j.electacta.2024.145266
  • 发表时间:
    2024-12-20
  • 期刊:
  • 影响因子:
    5.600
  • 作者:
    Arup Chakraborty;Tazdin Amietszajew
  • 通讯作者:
    Tazdin Amietszajew
Do Sleep Time and Duration Affect the Development of Prehypertension in Undergraduate Medical Students? An Experience from a Tertiary Care Hospital in Kolkata
睡眠时间和持续时间会影响医学生本科生高血压前期的发展吗?
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    1.6
  • 作者:
    Sayan Ali;Samit Karmakar;Arup Chakraborty;Saptarshi Ghosh
  • 通讯作者:
    Saptarshi Ghosh
Can Viral Geometry Determine B Cell Selection during an Immune Response?
  • DOI:
    10.1016/j.bpj.2018.11.2270
  • 发表时间:
    2019-02-15
  • 期刊:
  • 影响因子:
  • 作者:
    Assaf Amitai;Arup Chakraborty;Mehran Kardar
  • 通讯作者:
    Mehran Kardar
Deciphering Core, Valence, and Double-Core-Polarization Contributions to Parity Violating Amplitudes in 133Cs Using Different Many-Body Methods.
使用不同的多体方法破译 133C 中的核、价和双核极化对宇称违反振幅的贡献。

Arup Chakraborty的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arup Chakraborty', 18)}}的其他基金

Biophysics of Nuclear Condensates
核凝聚体的生物物理学
  • 批准号:
    2044895
  • 财政年份:
    2021
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Continuing Grant
Summer School and Workshops on Genome Architecture and Function
基因组结构和功能暑期学校和研讨会
  • 批准号:
    2015620
  • 财政年份:
    2020
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Standard Grant
RAISE: A Phase Separation Model for Transcriptional Control in Mammals
RAISE:哺乳动物转录控制的相分离模型
  • 批准号:
    1743900
  • 财政年份:
    2017
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Standard Grant
Exploiting Biomimetic Recognition between Polymers & Surfaces to Design Nanoscale Separation Processes
利用聚合物之间的仿生识别
  • 批准号:
    0001304
  • 财政年份:
    2000
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Continuing Grant
Statistical Pattern Matching Between Random Heteropolymers and Multifunctional Disordered Surfaces; Implications for Viral Inhibition and Chromatography
无规杂聚物与多功能无序表面之间的统计模式匹配;
  • 批准号:
    9711340
  • 财政年份:
    1997
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Standard Grant
NSF Young Investigator
NSF 青年研究员
  • 批准号:
    9257639
  • 财政年份:
    1992
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Continuing Grant

相似海外基金

Reduction of immunogenicity of SARS-CoV-2 vaccine in the elderly people: analysis by DNA methylation
老年人 SARS-CoV-2 疫苗免疫原性的降低:DNA 甲基化分析
  • 批准号:
    22K07447
  • 财政年份:
    2022
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Characterization of first- and second-generation RNA vaccine immunogenicity against SARS-CoV-2 variants of concern in Canada
第一代和第二代 RNA 疫苗针对加拿大关注的 SARS-CoV-2 变体的免疫原性特征
  • 批准号:
    459284
  • 财政年份:
    2021
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Operating Grants
Harnessing pre-existing immunity to enhance the immunogenicity of an adjuvant-free, immuno-targeting subunit vaccine against SARS-CoV-2
利用预先存在的免疫力来增强针对 SARS-CoV-2 的无佐剂、免疫靶向亚单位疫苗的免疫原性
  • 批准号:
    467139
  • 财政年份:
    2021
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Studentship Programs
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Lab
CoVPN 3004 - 一项 3 期随机、观察者盲法、安慰剂对照研究,旨在评估 SARS-CoV-2 重组刺突蛋白纳米颗粒疫苗实验室的功效、安全性和免疫原性
  • 批准号:
    10322580
  • 财政年份:
    2021
  • 资助金额:
    $ 12.45万
  • 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
  • 批准号:
    10415762
  • 财政年份:
    2021
  • 资助金额:
    $ 12.45万
  • 项目类别:
Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectors
外泌体展示作为增强基于腺病毒载体的 SARS-CoV-2 疫苗免疫原性的策略
  • 批准号:
    10363963
  • 财政年份:
    2020
  • 资助金额:
    $ 12.45万
  • 项目类别:
Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectors
外泌体展示作为增强基于腺病毒载体的 SARS-CoV-2 疫苗免疫原性的策略
  • 批准号:
    10161344
  • 财政年份:
    2020
  • 资助金额:
    $ 12.45万
  • 项目类别:
Transmission, pathogenesis and immunogenicity of SARS-CoV-2 in frontline healthcare workers: a national longitudinal cohort of 1320 participants
一线医护人员中 SARS-CoV-2 的传播、发病机制和免疫原性:由 1320 名参与者组成的全国纵向队列
  • 批准号:
    MR/V027883/1
  • 财政年份:
    2020
  • 资助金额:
    $ 12.45万
  • 项目类别:
    Research Grant
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine SDMC
CoVPN 3001 评估 mRNA-1273 SARS-CoV-2 疫苗 SDMC 的功效、安全性和免疫原性的 3 期、随机、分层、观察者盲法、安慰剂对照研究
  • 批准号:
    10217912
  • 财政年份:
    2020
  • 资助金额:
    $ 12.45万
  • 项目类别:
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques
SARS-CoV-2 稳定预灌注 Spike 蛋白疫苗在幼年恒河猴中的免疫原性和功效
  • 批准号:
    10223633
  • 财政年份:
    2020
  • 资助金额:
    $ 12.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了